Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery Chemoembolization After First-line Chemotherapy and Immunotherapy

Starting soon · Phase 4

Conditions studied: Lung Squamous Cell Carcinoma Stage IV

In brief

This study intends to carry out prospective, randomized controlled clinical trials in many centers across the country to compare the efficacy and safety of immunotherapy after standard first-line chemotherapy or immunotherapy combined with interventional bronchial artery chemoembolization for stage IV lung squamous cell carcinoma.

Key facts

Study ID

NCT07567313

Run by

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

People needed

166

Starts

2026-04-20

Expected to finish

2028-06-30

Last updated by the study team

2026-05-05

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Squamous cell carcinoma of the lung confirmed by histology or cytology;
• According to the TNM staging system of the 9th edition of American Cancer Association, it was assessed as stage IV.
• Has received standard first-line chemotherapy immunotherapy for 4\~6 cycles, and achieved partial remission or disease stability according to the efficacy evaluation of RECIST1.1;
• The patient is 18-80 years old;
• ECOG PS score is 0-1;
• The main organ functions meet the following criteria: (1) Blood routine examination: hemoglobin (HB) ≥ 90g/L; Leukocyte (ANC) ≥ 3.0× 109/L; Neutrophils ≥ 1.5× 109/L; Platelet (PLT) ≥ 75× 109/L; (2) Biochemical examination: albumin (ALB)≥29g/L; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2uln; Total bilirubin (TBIL) ≤ 1.5 ULN; Creatinine ≤ 1.5 ULN;
• Patients and/or their families agree to participate in clinical trials and sign informed consent forms;
• No history of other malignant tumors;
• No active infection;
• Be able to cooperate with research follow-up;
• At least one measurable lesion (according to RECIST 1.1);
• The expected survival time is more than 3 months.

You may not qualify if…

• There is epidermal growth factor receptor (EGFR) sensitive mutation or anaplasticlymphomakinase (ALK) gene translocation;
• Have a history of allergy to contrast agents or chemotherapy drugs;
• Received other anti-tumor treatments other than standard first-line chemotherapy immunotherapy;
• Arrhythmia with myocardial ischemia or myocardial infarction above grade II and poor control (including QTc interval ≥450ms for men and ≥ 470 ms for women);
• Coagulation function is seriously abnormal and cannot be corrected;
• Hypertension patients still have poor blood pressure control (systolic blood pressure > >160mmHg, diastolic blood pressure > 100 mmhg) after antihypertensive drugs treatment;
• Pregnant or lactating female patients;
• Have a history of mental illness or psychotropic drug abuse;
• Patients with symptomatic brain metastasis;
• Patients with autoimmune diseases;

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.